Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pear Therapeutics, Inc.

< Previous 1 2 3 Next >
Pear Therapeutics and Crossroads Treatment Centers to Provide More Patients Access to Prescription Digital Therapeutics as Standard of Care for the Treatment of Substance Use Disorders
From Pear Therapeutics, Inc.
Via Business Wire
Tickers PEAR
Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company
From Pear Therapeutics, Inc.
Via Business Wire
Tickers PEAR
Pear Therapeutics to Participate in Evercore ISI Fourth Annual HealthCONx Conference
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder
From Pear Therapeutics, Inc.
Via Business Wire
Thimble Point and Pear Therapeutics Announce Additional $50 Million in Committed Capital to Fund Business Plan
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in the BTIG Digital Health Forum
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics and Thimble Point Acquisition Corp. Announce Effectiveness of S-4 Registration Statement and Set November 23, 2021 for Thimble Point Special Stockholder Meeting to Vote on Proposed Business Combination
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Launches Pear Prescription Digital Therapeutics Digest, Provides Roadmap for Payer Coverage Considerations
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces First State Medicaid Program Decision to Cover Prescription Digital Therapeutics
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in HLTH 2021 Conference and Evercore ISI Digital Therapeutics Virtual Bus Tour
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Continues to Expand Intellectual Property Portfolio for Prescription Digital Therapeutics
From Pear Therapeutics, Inc.
Via Business Wire
Prime Therapeutics and Pear Therapeutics Announce First Comprehensive Value-based Agreement for Prescription Digital Therapeutics reSET® and reSET-O® for the Treatment of Substance and Opioid Use Disorders
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in the Sachs Associates 8th Annual HealthTech Investment Forum
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Additional Coverage Decisions and Formulary Adoption of its Prescription Digital Therapeutics
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in the DTx East 2021 Conference
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Publication of Real-World Data Showing Improved Clinical Outcomes with a Subsequent Prescription of reSET-O® for Patients with Opioid Use Disorder
From Pear Therapeutics, Inc.
Via Business Wire
Pear and Thimble Point Announce Nominees to Board of Directors
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Publication of Cost-Utility Data Showing Quality of Life and Cost Reduction with reSET-O® for the Treatment of Opioid Use Disorder
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Formulary Availability for its Three FDA Authorized Prescription Digital Therapeutics at OptumRx
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in Upcoming Investor Conferences
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces Publication of Healthcare Resource Utilization Data Analysis Showing Real-World Cost Impact of reSET-O® in Treating Opioid Use Disorder
From Pear Therapeutics, Inc.
Via Business Wire
Ninilchik Village Tribe Will Provide Access to Prescription Digital Therapeutics to Help Alaskan Community Treat Rural Patients with Substance and Opioid Use Disorders
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Reports Nine-Month Real-World Healthcare Utilization Data for reSET-O®
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Announces First Participant Enrolled in National Institutes of Health Clinical Trial Investigating Combinations of Pharmacological and Behavioral Interventions to Treat Opioid Use Disorder
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics and Serve You Rx Announce Formulary Coverage for Prescription Digital Therapeutic Somryst® and People with Chronic Insomnia
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Become a Public Company and Expand its Leadership Position in Prescription Digital Therapeutics
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics to Participate in Cowen 6th Annual FutureHealth Conference
From Pear Therapeutics, Inc.
Via Business Wire
Pear Therapeutics Presents Results of Two Analyses Showing Decreases in Healthcare Resource Utilization and Associated Costs in Patients Using reSET-O® in Treating Opioid Use Disorder
From Pear Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.